Nifty Pharma News and Updates

Name: Latest research reports of Natco Pharma Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Natco Pharma Ltd.
Rating: 3
Author: Geojit BNP Paribas

Keep track of all breaking news on Nifty Pharma from all sources in a single place.

Load latest

Natco Pharma Ltd.

17 Sep 2025

864.50

-2.23%

NATCO PHARMA

Hold: Natco Pharma Ltd.

Target

Geojit BNP Paribas

The management maintains a long-term perspective on the business, aiming to navigate potential challenges and seize growth opportunities. We anticipate a steep revenue degrowth because of lower Revlimid sales in FY27. Focus will shift on the domestic formulations business with the anticipated launches of Semaglutide, which strengthens our case for...

Natco Pharma Ltd. has an average target of 1294.50 from 4 brokers.

Abbott India Ltd.

17 Sep 2025

30195.00

-0.56%

Steady business, outpacing Pharma peers

Buy: Abbott India Ltd.

Target

Sharekhan

Strong history of product launches: Abbott India has been steadily growing led by consistent launches of both - own and Novo Nordisk’s products (marketing). Abbott India has launched over 100 products in India in the last 12 years and we expect the pipeline to stay strong.

Abbott India Ltd. is trading below all available SMAs

Gland Pharma Ltd.

16 Sep 2025

2014.80

-0.40%

Gland Pharma Gets Yes Securities' 'Add' Upgrade; Sees U.S., Cenexi Business as Key Growth Drivers

NDTV Profit

Yes Securities views Gland Pharma as a better proxy on US generics in the near term, hence hikes target price.

Gland Pharma Ltd. is trading above all available SMAs

Dr. Reddy's Laboratories Ltd.

15 Sep 2025

1301.40

-1.54%

Dr Reddy's shares fall as USFDA flags Hyderabad plant with 5 observations

Business Standard

Dr Reddy's shares fell on Monday after the USFDA issued a Form 483 with five observations at its Hyderabad plant inspection

Dr. Reddy's Laborato.. has an average target of 1278.56 from 9 brokers.

Lupin Ltd.

15 Sep 2025

2004.40

-2.49%

Lupin, Astra Microwave among top analyst bets; check target, stop-loss

Business Standard

Stocks to buy: Astra Microwave Products has shown a strong movement in the last trading session, while Lupin has recently undergone a notable resurgence

Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.

Lupin Ltd.

12 Sep 2025

2004.40

-2.49%

Lupin Shares Jump Over 3% As Investec Hikes Target Price, Upgrades To 'Buy'

NDTV Profit

Lupin shares rose as much as 3.37% to Rs 2,055 apiece. It last pared gains to trade 2.41% higher at Rs 2,036 apiece.

Lupin Ltd. is trading below its 200 day SMA of 2025.5

Buy Lupin, Says Investec After Stock Rating Upgrade; Share Price Target Hiked What's Driving Growth?

NDTV Profit | 12 Sep 2025

Biocon Ltd.

11 Sep 2025

362.15

-1.91%

Biocon expands US footprint with new Cranbury manufacturing facility

Business Standard

Biocon inaugurated its first US manufacturing facility in Cranbury through Biocon Generics, expanding its global footprint and strengthening supply chains for essential therapies

Institutional Investors have increased holdings from 21.40% to 28.87% in Jun 2025 qtr.

Biocon inaugurates first manufacturing facility in New Jersey's Cranbury

Business Standard | 11 Sep 2025 1 more

Dr. Reddy's Laboratories Ltd.

11 Sep 2025

1301.40

-1.54%

Dr Reddy's signs pact with J&J to acquire vertigo treatment brand

Business Standard

Dr Reddy's Laboratories on Thursday announced the completion of a definitive transaction with Johnson & Johnson to acquire Stugeron brand across the EMEA regions, with India and Vietnam as key markets. Stugeron contains Cinnarizine, an antihistamine indicated for the treatment of vestibular disturbances and vertigo. The acquisition presents a strategic opportunity for the Hyderabad-based drug firm to expand its footprint in the anti-vertigo space as well as strengthen its Central Nervous System (CNS) portfolio, Dr Reddy's Laboratories said in a statement. Dr Reddy's acquisition of the brand reflects a steady advancement in the company's efforts to expand into the anti-vertigo therapeutic segment, contributing to the continued development of CNS portfolio, said MV Ramana, CEO, Branded Markets (India and Emerging Markets), Dr Reddy's Laboratories. "Backed by our strong market access, we intend to extend the reach of Stugeron and its associated products across 18 key markets in the ..

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr Reddy's enters anti-vertigo segment with acquisition of Stugeron from Johnson & Johnson

Business Line | 11 Sep 2025 1 more

Dr. Reddy's Laboratories Ltd.

11 Sep 2025

1301.40

-1.54%

Stock Flash

Sell: Dr. Reddy's Laboratories Ltd.

Deven Choksey

Dr. Reddy’s Laboratories Ltd. has entered into a definitive agreement with Janssen Pharmaceutica NV, an affiliate of Johnson & Johnson, to acquire the STUGERON® brand along with its leading local brands STUGERON® FORTE and STUGERON® PLUS.

Dr. Reddy's Laborato.. has an average target of 1278.56 from 9 brokers.

Sun Pharmaceutical Industries Ltd.

09 Sep 2025

1644.00

-0.72%

Sun Pharma's Halol plant gets OAI classification from US FDA inspection

Business Standard

US FDA has classified Sun Pharma's Halol facility in Gujarat as OAI, keeping it under import alert, signalling possible enforcement action unless corrective steps are taken

Sun Pharmaceutical Industries Ltd. is trading above its 50 day SMA of 1638.8

Sun Pharma stock concerns may be overstated as domestic growth holds

Business Standard | 09 Sep 2025

Is Nifty Pharma worth buying?

324 Votes:

Buy 79.32%

Sell 11.73%

Hold 8.95%

Nifty Pharma PB	4.8
Nifty Pharma PE	32.5
Nifty Pharma DIV	0.7
Nifty Pharma EPS	689.2

Nifty Pharma PB

Nifty Pharma PE

Nifty Pharma DIV

Nifty Pharma EPS

Nifty Pharma News and Updates

Keep track of all breaking news on Nifty Pharma from all sources in a single place.